APA (7th ed.) Citation

WD, T., GM, C., H, B., L, G., A, E., M, B., . . . JC, T. (2025). Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(11), 2108. https://doi.org/10.1158/1078-0432.CCR-24-4128

Chicago Style (17th ed.) Citation

WD, Tap, et al. "Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 31, no. 11 (2025): 2108. https://doi.org/10.1158/1078-0432.CCR-24-4128.

MLA (9th ed.) Citation

WD, Tap, et al. "Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 31, no. 11, 2025, p. 2108, https://doi.org/10.1158/1078-0432.CCR-24-4128.